Jefferies on Amgen (AMGN): Elegrobart data not a 'significant competitive threat to Tepezza'
Tweet Send to a Friend
Jefferies analyst Akash Tewari reiterated a Hold rating and $350.00 price target on Amgen (NASDAQ: AMGN)The analyst commented, "We got ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
